🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

20 results for “Biogen” Clear

  1. 0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE

    Biogen Idec Ltd

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  2. BIIB059

    Biogen Idec Ltd

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen Idec Ltd

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  4. BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

    Biogen Idec Ltd

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  5. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

    Biogen Idec Ltd

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  6. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

    Biogen Idec Ltd

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  7. BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

    Biogen Idec Ltd

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  8. BIIB111

    Biogen Idec Ltd

    Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

    phase 3 small molecule active

    1 trial

  9. Hard capsules, BIIB141

    Biogen Idec Ltd

    Friedreich’s ataxia

    phase 3 small molecule active

    1 trial

  10. Plegridy 125 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., Plegridy 63 micrograms+94 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5 ml solution for injection.

    Biogen Idec Ltd

    Relapsing Remitting Multiple Sclerosis (RRMS)

    phase 3 small molecule active

    1 trial

  11. SPINRAZA 28 mg, SPINRAZA 50 mg

    Biogen Idec Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  12. SPINRAZA 50 mg, SPINRAZA 28 mg

    Biogen Idec Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  13. Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab

    Biogen Idec Ltd

    Kidney Transplant Recipients with Late Antibody-Mediated Rejection

    phase 3 small molecule active

    1 trial

  14. TECFIDERA

    Biogen Idec Ltd

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  15. Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion

    Biogen Idec Ltd

    Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

    phase 2 small molecule active

    1 trial

  16. Matching Placebo tablets without active substance, BIIB122

    Biogen Idec Ltd

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  17. X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

    Biogen Idec Ltd

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  18. BiiB115 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of BIIB115 drug product minus the active ingredient, BIIB115

    Biogen Idec Ltd

    Spinal muscular atrophy

    phase 1 small molecule active

    1 trial

  19. Spinraza 12 mg solution for injection

    Biogen Idec Ltd

    Spinal Muscular Atrophy

    phase 1 small molecule active

    1 trial

  20. Spinraza 12 mg solution for injection

    Biogen Idec Ltd

    Spinal Muscular Atrophy

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources